Biolinerx Ltd. income statement

In fiscal 2025, Biolinerx Ltd. reported revenue of $1.2m, down 95.9% on the year before, operating income of −$10.3m (a -871.8% margin) and net income of −$2.0m. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Biolinerx Ltd.: income statement, annual
Fiscal year	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	0	0	5	29	1
Cost of revenue	0	0	4	9	0
Gross profit	0	0	1	20	1
Research and development	19	18	13	9	8
Operating income	−25	−29	−50	−20	−10
Interest expense	1	2	2	9	1
Income tax	0	0	0	0	0
Net income	−27	−25	−61	−9	−2
Diluted EPS	−$12.00	−$9.00	−$18.00	—	—
Diluted shares (average)	2m	3m	3m	4m	4m
EBITDA	−24	−29	−49	−20	−10

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: BLRX vs LGVN BLRX vs DARE BLRX vs STTK

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Biolinerx Ltd.'s SEC filings (10-K and 10-Q), retrieved November 2, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Biolinerx Ltd.